MedPath

Premixed Injectable MTA for Pulpotomy of Primary Teeth

Not yet recruiting
Conditions
Dental caries indicated for Pulpotomy without irreversible pulpal damage
Pulpitis,
Registration Number
CTRI/2023/07/055519
Lead Sponsor
AISWARYA U S
Brief Summary

Pulpotomy is vital endodontic procedure done to maintain the integrity of the radicular pulp. This study will be done to evaluate the clinical and radiographic outcome of Premixed Injectable MTA and Conventional MTA as pulpotomy medicament in primary teeth.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
15
Inclusion Criteria

Children with bilateral indication for pulpotomy without signs and symptoms of irreversible pulpal damage.

Exclusion Criteria

Children with irreversible pulpal damage, sinus or fistula and children with systemic diseases.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Injecatble form of MTA can be used as a Pulpotomy Medicament in Primary teeth. Clinical and radiographic assessment will be done.Over a period of 6 months and one year
Secondary Outcome Measures
NameTimeMethod
Clinical & radiographic outcome of the pulpotomy with premixed injectable MTA will be assessed over a follow up period12 months

Trial Locations

Locations (1)

Yenepoya Dental College

🇮🇳

Kannada, KARNATAKA, India

Yenepoya Dental College
🇮🇳Kannada, KARNATAKA, India
Dr Aiswarya U S
Principal investigator
8220083144
aishuaish59@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.